Ionis Pharmaceuticals Inc (IONS) Stake Boosted by Bellevue Group AG

Evrard Martin
Juin 3, 2017

State Board of Administration of Florida Retirement System reduced its stake in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 2.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). They use historic price data to observe stock price patterns to predict the direction of that price going forward.

A number of large investors have recently modified their holdings of IONS. Needham & Company LLC reiterated a "buy" rating and set a $64.00 target price on shares of Ionis Pharmaceuticals in a research report on Monday, March 6th. Goldman Sachs Group Inc downgraded shares of Ionis Pharmaceuticals from a "neutral" rating to a "sell" rating and cut their price target for the company from $28.00 to $25.00 in a report on Friday, March 10th. BMO Capital Markets restated an "outperform" rating and issued a $59.00 price target on shares of Ionis Pharmaceuticals in a research note on Wednesday, April 26th. Finally, Candriam Luxembourg S.C.A. acquired a new stake in shares of Ionis Pharmaceuticals during the third quarter valued at approximately $3,298,000. Three analysts have rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating to the stock. The third largest holder is Vanguard Group Inc, which now holds $432.16 million worth of this stock and that ownership represents almost 7.23% of its market capitalization.

Ionis Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $47.67. BMO Capital Markets increased their price target on shares of Ionis Pharmaceuticals from $32.00 to $35.00 and gave the stock an outperform rating in a research note on Thursday, May 11th. The firm's 50-day moving average is $44.47 and its 200-day moving average is $44.97.

In the last earnings report the EPS was $-0.17 and is projected to be $-0.39 for the current year with 123,965,000 shares now outstanding. The business had revenue of $110.30 million for the quarter, compared to analysts' expectations of $86.03 million. Ionis Pharmaceuticals had a negative net margin of 77.30% and a negative return on equity of 120.60%. The business's revenue for the quarter was up 199.2% compared to the same quarter previous year.

Several analysts have released their opinion on Ionis Pharmaceuticals, Inc. The original version of this article can be read at If you are accessing this article on another publication, it was copied illegally and republished in violation of global trademark and copyright law. The shares were sold at an average price of $49.29, for a total transaction of $73,935.00. After this sale, 10,449 common shares of IONS are directly owned by the insider, with total stake valued at $503,955.

Ionis Pharmaceuticals Inc (NASDAQ:IONS) SVP Patrick R. O'neil sold 500 shares of the firm's stock in a transaction dated Monday, April 24th.

On 4/13/2017 Stanley T Crooke, Chairman, sold 22,000 with an average share price of $40.69 per share and the total transaction amounting to $895,180.00. Following the transaction, the chairman now owns 48,014 shares in the company, valued at $1,953,689.66. (NASDAQ:IONS). Frederick T. Muto, Director disclosed the sale of 12,500 shares of (IONS). Insiders sold a total of 46,150 shares of company stock worth $2,016,178 over the last 90 days. Franklin Resources Inc. raised its stake in shares of Ionis Pharmaceuticals by 2.6% in the fourth quarter. Raymond James Trust N.A. now owns 5,705 shares of the company's stock valued at $229,000 after buying an additional 159 shares during the period. Highbridge Capital Management LLC raised its position in Ionis Pharmaceuticals by 4,929.4% in the third quarter. LLC purchased a new stake in shares of Ionis Pharmaceuticals during the fourth quarter valued at $143,000. Comerica Bank raised its position in shares of Ionis Pharmaceuticals by 33.3% in the fourth quarter. The institutional investor owned 167,356 shares of the company's stock after selling 4,079 shares during the period.

Institutional investors now hold around $5.11 billion or 91.6% in IONS stock.

About Ionis Pharmaceuticals Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Ionis Core segment involves a a novel drug discovery platform generate a broad pipeline of drugs.

D'autres rapports CampDesrEcrues

Discuter de cet article